Compare STEM & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | CRBU |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 179.7M |
| IPO Year | 2020 | 2021 |
| Metric | STEM | CRBU |
|---|---|---|
| Price | $11.85 | $2.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.33 | $10.75 |
| AVG Volume (30 Days) | 102.3K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | N/A |
| Revenue This Year | $2.77 | $1.63 |
| Revenue Next Year | $14.65 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $0.35 | $0.73 |
| 52 Week High | $32.23 | $3.53 |
| Indicator | STEM | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 67.00 |
| Support Level | $10.93 | $1.70 |
| Resistance Level | $12.05 | $2.66 |
| Average True Range (ATR) | 0.72 | 0.11 |
| MACD | 0.34 | 0.03 |
| Stochastic Oscillator | 89.37 | 88.18 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.